TABLE 5.
Diagnostic performances of B-US-RS, SWE-RS, quantitative SWE parameters, and BI-RADS assessment in the external validation cohort.
| Parameter | Threshold | Sensitivity (%)* | Specificity (%)* | AUC* | Positive likelihood ratio | Negative likelihood ratio |
| B-US-RS | −1.28 | 100 (79–100) [10/10] | 100 (90–100) [18/18] | 1.00 (1.00–1.00) | ∞ | 0 |
| SWE-RS | −0.24 | 100 (79–100) [10/10] | 100 (90–100) [18/18] | 1.00 (1.00,1.00) | ∞ | 0 |
| Quantitative SWE parameter | ||||||
| Emax (kPa) | >46.45 | 70 (35–92) [7/10] | 89 (64–98) [16/18] | 0.90 (0.77–1.00) | 6.30 (1.60–24.75) | 0.34 (0.13–0.88) |
| Emean (kPa) | >35.35 | 70 (35–92) [7/10] | 94 (71–100) [17/18] | 0.86 (0.69–1.00) | 12.6 (1.80–88.34) | 0.32 (0.12–0.82) |
| Eratio (kPa) | >4.15 | 70 (35–92) [7/10] | 89 (64–98) [16/18] | 0.86 (0.69–1.00) | 6.30 (1.60–24.75) | 0.34 (0.13–0.88) |
| ESD (kPa) | >10.35 | 80 (44–96) [8/10] | 89 (64–98) [16/18] | 0.89 (0.75–1.00) | 7.20 (1.88–27.58) | 0.22 (0.06–0.79) |
| Combined quantitative SWE parameters | −0.87 | 70 (35–92) [7/10] | 94 (71–100) [17/18] | 0.88 (0.73–1.00) | 12.6 (1.80–88.34) | 0.32 (0.12–0.82) |
| BI-RADS category at US | >3 | 90 (54–100) [9/10] | 39 (18–64) [7/18] | 0.87 (0.70–1.00) | 1.47 (0.96–2.25) | 0.26 (0.03–1.96) |
Data in parentheses are 95% confidence intervals and data in brackets are raw data. US, ultrasonography; RS, radiomics signature; SWE, shear-wave elastography; BI-RADS, Breast Imaging Reporting and Data System; and AUC, area under the curve. * P values for statistical significance are corrected to 0.008 for multiple testing using Bonferroni correction.